vemurafenib
1 clinical trial
8 abstracts
1 indication
Indication
MelanomaAbstract
Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.Org: Deparment of Medical Oncology, IRCCS Ospedale Policlinico San Martino, Immunotherapy and Cell Therapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, IRCCS Istituto Oncologico di Bari Giovanni Paolo II, Oncology Department, Institute of Dermatology, Catholic University Fondazione Policlinico Universitario, Medical Oncology Unit, Department of Oncology, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro,
Clinical trial
A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaStatus: Active (not recruiting), Estimated PCD: 2016-11-09
Abstract
Longitudinal assessment of cardiac involvement in Erdheim-Chester disease using cardiac magnetic resonance imaging.Org: Hôpital Pitié-Salpêtrière, Service de Médecine Interne 2, Hôpital Pitié Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP), Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
A powerful drug combination strategy targeting BRAF-mutant melanoma.Org: University Hospitals Sussex NHS Foundation Trust, Seidman Cancer Center, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center,
Abstract
VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer.Org: Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University; Department of General Surgery Depart.2 (Colorectal Gastrointestinal Surgery), West China Tianfu Hospital, Sichuan University, Chengdu, China, Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan, Zhongshan Hospital, Fudan University, Shanghai, China, Shanghai, China, Gracell Biotechnologies, Ltd., Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China,
Abstract
Skin adverse events of anti-cancer treatments: An examination of drug-AE associations.Org: La Roche-Posay International, Levallois-Perret, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, Memorial Sloan Kettering Cancer Center,
Abstract
A pilot study of the neoadjuvant use of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma with palpable lymph node metastases: Survival results.Org: Sunnybrook Hospital, Royal Victoria Hospital/Glen Site/Cedar Cancer Centre, Department of Surgery, University of Ottawa-Ottawa General Hospital, Jewish General Hospital Stroll Cancer Prevention Centre, Lady Davis Institute, McGill University,
Abstract
Efficacy of vemurafenib based regimens in colorectal cancer: A systematic review of clinical trials.Org: New York Medical College - Saint Michael's Medical Center, Saint Michael's Medical Center, St. Michael's Medical Ctr, Reg Cancer Ctr At St Michael's Medical Ctr,
Abstract
Correlations between overall response rate, progression-free survival and overall survival with kinase inhibitors in radioiodine-refractory differentiated thyroid cancers: A systematic review and meta-analysis.Org: One Brooklyn Health/Brookdale University Hospital and Medical Center, Brooklyn ImmunoTherapeutics, Nykode Therapeutics,